Stock Research: Roche

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Roche

VTX:ROG CH0012032048
10
  • Value
    59
  • Growth
    31
  • Safety
    Safety
    17
  • Combined
    9
  • Sentiment
    24
  • 360° View
    360° View
    10
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Roche Holding AG is a healthcare company focused on pharmaceuticals and diagnostics. The company operates in the pharmaceuticals and diagnostics industries with business segments in Pharmaceuticals (Roche Pharmaceuticals and Chugai) and Diagnostics (Diabetes Care, Molecular Diagnostics, Professional Diagnostics, and Tissue Diagnostics). The company develops medicines for oncology, immunology, infectious diseases, ophthalmology, and neuroscience. In the last fiscal year, the company had a market cap of $258,542 million, profits of $49,371 million, and revenue of $66,683 million, with 103249 employees.

more
Index
SPI
SPI
SMI
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 19-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
59 51 61 50
Growth
31 55 17 31
Safety
Safety
17 14 30 45
Sentiment
24 79 64 14
360° View
360° View
10 45 30 24
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
13 24 26 55
Opinions Change
43 75 54 16
Pro Holdings
n/a 92 63 30
Market Pulse
39 67 79 39
Sentiment
24 79 64 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
59 51 61 50
Growth
31 55 17 31
Safety Safety
17 14 30 45
Combined
9 22 14 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
50 31 39 36
Price vs. Earnings (P/E)
56 56 70 58
Price vs. Book (P/B)
21 10 12 10
Dividend Yield
78 87 90 86
Value
59 51 61 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
16 34 25 12
Profit Growth
52 51 29 37
Capital Growth
59 51 46 39
Stock Returns
51 80 36 76
Growth
31 55 17 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
16 12 20 43
Refinancing
20 22 21 14
Liquidity
55 63 73 74
Safety Safety
17 14 30 45

Similar Stocks

Discover high‑ranked alternatives to Roche and broaden your portfolio horizons.

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Zehnder Group

SWX:ZEHN
Country: Switzerland
Industry: Building Products
Size: Medium
Full Stock Analysis

Krka

LJU:KRKG
Country: Slovenia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Siegfried

SWX:SFZN
Country: Switzerland
Industry: Life Sciences Tools & Services
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a highly risky stock investment proposition as all consolidated ranks are below-average. There are no compelling arguments to support this stock based on current information. It is not recommended for any investor profile. However, performance does change, so it could we worth keepin on a watchlist.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: